Amanta Healthcare IPO: A new investment opportunity opening from September 1
The beginning of September is going to be a big opportunity for stock market investors. Ahmedabad-based parenteral products maker Amanta Healthcare is coming to Dalal Street with an IPO, its first public issue. This IPO of the healthcare sector has already created a buzz, as the company has reduced its offer size but has kept the growth objectives the same. This IPO can become an exciting chance for those who want to be a part of the growth story of the pharma sector.
Amanta Healthcare IPO launch date and details
Amanta Healthcare will launch its IPO on 1 September 2025. In this IPO, the company is coming with only a fresh issue, in which 1 crore equity shares will be issued. Earlier the plan was to bring 1.25 crore shares to the market, but later it was reduced to 1 crore shares.
The anchor book for institutional investors will open on 29 August, while retail and other investors can place their bids from 1 September to 3 September. The IPO allotment will be finalized on 4 September and from 8 September the shares will start trading on BSE and NSE.
Utilization of funds – focus of Amanta Healthcare
The biggest thing is that the company has clearly defined the utilization of its IPO proceeds. Approximately ₹70 crore will be used for civil construction and ₹30.13 crore will be invested in purchasing new plant and machinery. This investment is for their new manufacturing line which will include SteriPort (large volume parenterals) and SVP (small volume parenterals), which will be set up at Hariyala, Gujarat plant.
The remaining amount will be kept for general corporate purposes, which will give financial flexibility to the company. One thing is clear from this – IPO money is going to be spent on direct growth and infrastructure.
Amanta Healthcare shareholding and promoters
Before the launch of IPO, promoters of Amanta Healthcare held approximately 85.6% shares. The remaining 14.4% is held by the public, which includes alternative investment funds such as Finavenue Growth Fund. The IPO is expected to see wider investor participation, which is positive for both the company’s image and growth in the long term.
Business and product portfolio
Amanta Healthcare is an established name in the pharma sector. The company manufactures large and small volume parenterals, which include IV fluids, fluid therapy solutions, diluents, ophthalmic and respiratory care products. Apart from this, the company also manufactures medical devices such as irrigation solutions, eye lubricants and first-aid solutions.
Given the increasing scale of healthcare demand, the funding received from the Amanta Healthcare IPO will further strengthen their production capacity.
Financial performance – solid jump in profits
If we talk about financials, the company’s performance has been a bit inconsistent in the last few years. But a strong turnaround was seen in FY25 (March 2025 ending year). The company’s profit jumped 189% to ₹10.50 crore, while the previous year’s profit was just ₹3.63 crore.
Revenue dipped slightly, falling 2% to ₹274.7 crore. But still the profit increased so much because the company cut down its finance and depreciation costs and improved operating margins. EBITDA also grew by 3.8% to Rs 59.7 crore and margin reached 21.72%. This shows that the company is using its resources more efficiently.
These numbers give a strong signal that Amanta Healthcare is taking its business in a profit-oriented direction, and hence Amanta Healthcare can become an interesting pick for IPO investors.
Merchant banker and IPO management
Beeline Capital Advisors has been appointed as the sole merchant banker for this IPO. Their job is to execute the IPO smoothly and reach maximum investors. Amanta Healthcare IPO can be an attractive entry point amidst the ongoing growth wave in the Pharma sector.
Final thoughts on Amanta Healthcare IPO
Healthcare industry has always been an essential sector and now through Amanta Healthcare IPO, investors are getting a new growth-oriented investment option. The company has kept its fund utilization clear, improved its financial performance and has made a strategy to expand its product portfolio.
For investors, this IPO is a chance to join a company that is trying to build a strong footprint in healthcare manufacturing. Yes, one should be a little cautious about revenue fluctuations, but profit growth and expansion plans are definitely a positive signal.
Disclaimer:
This article is for informational purposes only. Do not consider it as financial or investment advice. Before investing in any IPO or stock, please consult your financial advisor.
Also Read
Shreeji Shipping IPO: Subscribed 7.55 Times, GMP at 11% – Should You Invest?
